Aldosterone

Capa
Elsevier, 15 de fev. de 2019 - 300 páginas

Aldosterone, Volume 109, the latest release in the Vitamins and Hormones series first published in 1943, covers the field of hormone action, vitamin action, X-ray crystal structure, physiology and enzyme mechanisms, with this release focusing on topics relating to Aldosterone Research, Aldosterone and Micrornas, the Evolution of the Mineralocorticoid Receptor, Aldosterone and Kidney Micrornas, Adipocyte Mineralocorticoid Receptor, Regulation of Aldosterone Secretion, Leptin and Aldosterone, Cell- and Ligand-Specific Interactions in Mineralocorticoid Receptor Signaling, Primary Aldosteronism, Present and Future, Aldosterone-Producing Adenomas, Overexpression of the Mineralocorticoid Receptor, Aldosterone and Myocardial Pathology, and much more.



  • Focuses on the newest aspects of hormone action in connection with diseases, with this update focusing on aldosterone
  • Lays the groundwork for the focus of new chemotherapeutic targets
  • Represents reviews on emerging areas in hormone action, cellular regulators and signaling pathways
 

Conteúdo

Contents
18
The MR Consists of Multiple Functional Domains
19
Diverse Steroids Have High Affinity for the MR
26
16
31
Mechanisms of Mineralocorticoid Receptor Signaling
37
Regulation of Aldosterone Signaling by MicroRNAs
69
MiR Regulation of Aldosterone Signaling
76
MiR Regulation of Other Kidney Transporters and Regulatory Proteins
82
Inhibitors of Aldosterone Synthase
211
Weldon and Nicholas F Brown 1 Aldosterone in Health and Disease
212
Aldosterone Synthase Inhibitors
215
The Next Generation of Aldosterone Synthase Inhibitors
229
Summary and Conclusions
232
Regulation of Aldosterone Secretion
241
The ReninAngiotensin System
247
Other Regulators of Aldosterone Secretion
253

Acknowledgments
93
Aldosterone and Ion Channels
105
NonGenomic Effects of Aldosterone
133
Mineralocorticoid Receptor Antagonists
151
Anneli Nordqvist and Kenneth L Granberg 1 Clinical Use of Mineralocorticoid Receptor Antagonists
152
Specific Challenges in Designing Mineralocorticoid Receptor Antagonists
154
MR Antagonists That Fit in the Aldosterone Binding Site
156
MR Antagonists That Utilize the Met852 Pocket
158
The Helix 67 Induced Pocket
170
Aromatic Sulfonamides as MR Antagonists
171
Pyrrole Derivatives as MR Antagonists
172
The 14Dihydropyridine Class of MR Antagonists
174
The Pyrazoline Class of MR Antagonists
177
Oxazolidinone Derivatives as MR Antagonists
179
MR Antagonists With a Tricyclic Scaffold
181
Summary
182
Michael E Baker
184
Adipocyte Mineralocorticoid Receptor
189
The Adipose Organ
190
Adipocyte Mineralocorticoid Receptor MR and Adipogenesis
194
MR and Adipose Tissue Inflammation
195
Relationship Between MR Signaling and Browning of WAT
196
Novel Concepts Explaining the ObesityRelated Hyperaldosteronism
198
Role of AldosteroneMR System in Metabolic Syndrome
200
Use of MR Antagonists in Obesity and Metabolic Syndrome
202
Conclusions
203
Acknowledgments
259
Leptin and Aldosterone
265
Implications for the Sex Discrepant LeptinAldosterone Relationship
272
Conclusion and Perspectives
278
Present and Future
285
The FuturePrevalence
292
Primary aldosteronism PA for primary care practitioners PCPs
298
Introduction
304
Genomic and Nongenomic Signaling Pathways Activated Downstream
387
AldoMR System
391
From Cardiac Fibrosis to HF
394
Targeting AldosteroneMRSignaling Pathway as a Novel Strategy to Treat HF Patients
396
Conclusions
398
References
400
AldosteroneProducing Adenomas
407
Introduction
408
Epidemiology of PA
409
Pathophysiology and Genetic Disturbances
410
Low Renin HypertensionInappropriate Aldosterone Secretion
420
SideEffects of PA
421
Diagnostics
422
Treatment
424
Outcome
425
Summary
426
Direitos autorais

Outras edições - Ver todos

Termos e frases comuns

Sobre o autor (2019)

Dr. Gerald Litwack obtained M.S. and PhD degrees from the University of Wisconsin Department of Biochemistry and remained there for a brief time as a Lecturer on Enzymes. Then he entered the Biochemical Institute of the Sorbonne as a Fellow of the National Foundation for Infantile Paralysis. He next moved to Rutgers University as an Assistant Professor of Biochemistry and later as Associate Professor of biochemistry at the University of Pennsylvania Graduate School of Medicine. After four years he moved to the Temple University School of Medicine as Professor of Biochemistry and Deputy Director of the Fels Institute for Cancer Research and Molecular Biology, soon after, becoming the Laura H. Carnell Professor. Subsequently he was appointed chair of Biochemistry and Molecular Pharmacology at the Jefferson Medical College as well as Vice Dean for Research and Deputy Director of the Jefferson Cancer Institute and Director of the Institute for Apoptosis. Following the move of his family, he became a Visiting Scholar at the Department of Biological Chemistry of the Geffen School of Medicine at UCLA and then became the Founding Chair of the Department of Basic Sciences at the Geisinger Commonwealth School of Medicine, becoming Professor of Molecular and Cellular Medicine and Associate Director of the Institute for Regenerative Medicine at the Texas A&M Health Science Center as his final position. During his career he was a visiting scientist at the University of California, San Francisco and Berkeley, Courtauld Institute of Biochemistry, London and the Wistar Institute. He was appointed Emeritus Professor and/or Chair at Rutgers University, Thomas Jefferson University and the Geisinger Commonwealth School of Medicine. He has published more than 300 scientific papers, authored three textbooks and edited more than sixty-five books. Currently he lives with his family and continues his authorship and editorial work in Los Angeles.

Informações bibliográficas